Mean corpuscular volume in *HFE* p.C282Y/p.H63D compound heterozygotes with high iron phenotypes: clinical and laboratory associations

Running title: MCV in *HFE* p.C282Y/p.H63D compound heterozygotes

James C. Barton[1,2], J. Clayborn Barton[2], and Ronald T. Acton[2,3]

[1] Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA

[2] Southern Iron Disorders Center, Birmingham, Alabama, USA

[3] Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, USA

James C. Barton (corresponding author): bartonjames336@gmail.com; ORCID 0000-0003-2876-8276

J. Clayborn Barton: jbarton205@gmail.com; ORCID 0000-0002-2646-4466

Ronald T. Acton: rtakma@bellsouth.net; ORCID 0000-0002-8586-6887

Abstract

Background: Variables that influence mean corpuscular volume (MCV) in *HFE* p.C282Y (rs1800562)/p.H63D (rs1799945) compound heterozygotes are inadequately defined.

Methods: We retrospectively studied self-reported non-Hispanic white adult compound heterozygotes with transferrin saturation (TS) >50% and serum ferritin (SF) >300 μg/L (men) or TS >45% and SF >200 μg/L (women) who participated in primary care-based screening. In post-screening evaluations, we excluded participants with anemia, pregnancy, or medication use that increases MCV. We defined heavy alcohol intake as >28 g/d men and >14 g/d women. We determined associations of MCV with 11 clinical and laboratory variables.

Results: There were 74 participants (37 men, 37 women) of mean age 59±12 (SD) y. Mean screening TS and SF were 65±13% and 529±169 μg/L (men) and 59±14% and 376±195 μg/L (women). Post-screening values did not differ significantly. Mean MCV was 95.7±4.0 fL. There was a negative correlation of MCV with body mass index (p=0.0488) and positive correlations of MCV with age (p=0.0098), daily heme iron intake (p=0.0333), and daily alcohol intake (p=0.0113). Mean MCVs of 19 participants with and 55 without heavy alcohol intake were 97.8±3.8 g/d and 95.0±3.9 g/d, respectively; p=0.0074). Linear regression on MCV confirmed positive associations with age (p=0.0064) and daily alcohol intake (p=0.0151). MCV was not significantly associated with sex, diabetes, daily intakes of non-heme and supplemental iron, swollen or tender 2nd/3rd metacarpophalangeal joints, TS, or SF.

Conclusion: MCV in *HFE* p.C282Y/p.H63D compound heterozygotes with high iron phenotypes is positively associated with age and daily alcohol intake, after adjustment for other variables.

Introduction

HFE, the homeostatic iron regulator (chromosome 6p22.2),[1 2] encodes the cell surface glycoprotein HFE, an upstream regulator of the hepatic hormone hepcidin (*HAMP,* chromosome 19q13.12), the central controller of iron homeostasis.[3] In persons of European descent, the most common *HFE* missense mutations are p.C282Y (rs1800562) and p.H63D (rs1799945).[4] The estimated prevalence of p.C282Y/p.H63D compound heterozygotes in non-Hispanic white adults in North America is 1 in 49.[5] In persons of European descent in the United Kingdom, the estimated prevalence of p.C282Y/p.H63D compound heterozygotes is 1 in 31.[4]

Mean corpuscular volume (MCV) is the average size of red blood cells.[6] In Western Australia, mean MCVs of *HFE* p.C282Y/p.H63D compound heterozygotes were significantly higher than those of subjects without either p.C282Y or p.H63D (*HFE* wt/wt) but were not abnormally elevated.[7 8] In contrast, the mean MCVs of referred p.C282Y/p.H63D compound heterozygotes in Alabama[9] and the Netherlands[10] and corresponding wt/wt control subjects did not differ significantly. In genome-wide association studies of adults of European descent, there were positive statistical associations between MCV and p.C282Y[11 12 13] and p.H63D,[11] although HFE protein is not expressed in erythroid colonies.[14] We found no comprehensive study of the relationships between MCV and clinical and laboratory variables in adults with p.C282Y/p.H63D compound heterozygosity.

We performed a retrospective study of 74 adult self-reported non-Hispanic white *HFE* p.C282Y/p.H63D compound heterozygotes who 1) had both elevated TS and elevated SF in a population screening program[15] and 2) did not have anemia, report pregnancy, or use medications

that increase MCV. The aim of this study was to define the relationships between MCV and the following clinical and laboratory variables: age, sex, BMI, diabetes, daily intakes of heme, non-heme, and supplemental iron, daily intakes of alcohol, swollen or tender 2nd/3rd metacarpophalangeal (MCP) joints, TS, and SF. We compare the present observations with those of previously reported hemochromatosis and population cohorts and propose the relevance of the present results.

Methods

Ethics approval statement

The Hemochromatosis and Iron Overload Screening (HEIRS) Study, conducted by the National Heart, Lung, and Blood Institute and the National Human Genome Research Institute, in accordance with the principles of the Declaration of Helsinki, evaluated diverse aspects of hemochromatosis, iron overload, and iron-related disorders in a primary care-based sample of 101,168 adults enrolled during the interval 2001-2002 at four Field Centers in the U.S. and one in Canada.[5 15 16]

Local Institutional Review Boards of the HEIRS Study Coordinating Center (Wake Forest University Institutional Review Board, Wake Forest University), the HEIRS Study Central Laboratory (University of Minnesota Institutional Review Board, University of Minnesota), and the HEIRS Study Field Centers (Medical Institutional Review Board, Howard University; UAB Institutional Review Board for Human Use, University of Alabama at Brimingham; University of California Irvine Institutional Review Board, University of California Irvine; Committee for the Protection of Human Subjects/Institutional Review Board, University of Oregon in collaboration with the University of Hawaii Biomedical Institutional Review Board, University of Hawaii/Honolulu; and London Health Sciences Centre Research Institute, London Health Sciences Centre) gave ethical approvals of the Study protocol that is described in detail elsewhere.[5 15 16]

Participant consent statement

HEIRS Study participants ≥ 25 years of age were recruited from outpatient facilities affiliated with the Field Centers and gave written informed consent for screening and post-screening evaluation.[5]

[15 16] The HEIRS Study informed consent forms, not available as public documents, were used during the participant recruitment phase of the Study (2001-2002). Each of the Field Centers in North America used an Institutional Review Board-approved consent form tailored to its specific institution.[5 15 16]

Primary care-based screening

The HEIRS Study recruited participants from public and private primary care offices in ambulatory clinics, a health maintenance organization, and diagnostic blood collection centers affiliated with five Field Centers.[5] Ninety-eight percent of self-reported non-Hispanic white participants were recruited at Field Centers in Alabama, California, Ontario, and Oregon/Hawaii.[17] Laboratory testing at screening included only TS and SF phenotyping and *HFE* p.C282Y and p.H63D allele-specific genotyping.[5] p.C282Y/p.H63D compound heterozygosity was identified in 908 of 44,082 non-Hispanic white adult screening participants (2.06% [95% confidence interval (CI): 1.93, 2.91]).[17] Medical histories were not compiled and physical examinations were not performed at primary care-based screening.

Post-screening evaluation attendees

Invitations to attend post-screening evaluations were extended to all 78 participants with *HFE* p.C282Y/p.H63D compound heterozygosity whose screening TS and SF values were elevated (TS >50% and SF >300 μg/L for men; TS >45% and SF >200 μg/L for women).[15 18] Post-screening evaluation attendees included 77 of the 78 invitees (39 men, 38 women). We excluded two men and one woman because they had anemia (hemoglobin (Hb) <130 g/L (men) and <120 g/L

111 (women), pregnancy, or medication use that increased MCV.[19] The cohort for analysis consisted
112 of 74 participants (37 men, 37 women).
113
114 **Post-screening evaluations**
115 Evaluations included the following: 1) questionnaires completed by participants that addressed
116 medical histories and medications;[18] 2) University of Hawaii Multiethnic Dietary
117 Questionnaires;[18 20] 3) focused physical examinations performed by HEIRS Study physicians;[18]
118 and 4) laboratory testing of blood specimens.[18] The median interval between primary care-based
119 screening and post-screening evaluations was eight months.[18]
120
121 **Medical history questionnaires**
122 We defined reports of diabetes as affirmative responses to this question: "Have you ever been told
123 you have diabetes?" We defined reports of cirrhosis as affirmative responses to this question: "Ever
124 told that you have/had cirrhosis?"
125
126 **Dietary questionnaires**
127 Analyses of Multiethnic Dietary Questionnaires at the University of Hawaii provided estimates of
128 the average daily intakes of dietary iron, supplemental iron, and alcohol for the previous year.[18 20]
129 The dietary iron attributed to intakes of meat, fish, and poultry was classified as heme iron and
130 other dietary iron as non-heme iron. Iron intakes were expressed as mg/d. Alcohol intakes were
131 expressed as g/d. We defined heavy alcohol intake as the average intake of more than 14 standard
132 drinks per week (> 28 g/d) for men and more than 7 standard drinks per week (> 14 g/d) for
133 women.[21]

134

135 **Physical examinations**

136 We used Quetelet's formula (kg/m^2) to measure body mass index (BMI).[22] Physicians recorded
137 the presence or absence of swelling or tenderness of the 2nd/3rd metacarpophalangeal (MCP)
138 joints.[18]

139

140 **Laboratory testing**

141 Blood samples for post-screening testing were obtained after an overnight fast. All participants
142 were tested for *HFE* genotype confirmation, complete blood count, TS, and SF.[5] Serum alanine
143 aminotransferase (ALT) and aspartate aminotransferase (AST) levels were available in 46
144 participants (62.2%). All testing was performed at the HEIRS Study Central Laboratory (Fairview-
145 University Medical Center Clinical Laboratory, University of Minnesota, Fairview, MN, USA).[15]
146 [18] Respective mean TS and mean SF values in men and women in screening and post-screening
147 evaluations did not differ significantly (Table 1).

148

149 **Table 1.** Iron phenotypes in 74 *HFE* p.C282Y/p.H63D compound heterozygotes[a]

Men (n = 37)	**Screening**	**Post-screening evaluation**	**Value of p**
Mean transferrin saturation, % ± 1 SD	65 ± 13	58 ± 17	0.0692
Mean serum ferritin, µg/L ± 1 SD	529 ± 169	531 ± 170	0.9684
Women (n = 37)			
Mean transferrin saturation, % ± 1 SD	59 ± 14	53 ± 12	0.0594
Mean serum ferritin, µg/L ± 1 SD	376 ± 195	366 ± 201	0.8316

150 [a] SD, standard deviation

151

152 **Markers of advanced hepatic fibrosis or cirrhosis**

153 We calculated fibrosis-4 (FIB-4) indices[23] and AST-to-platelet ratio indices (APRI)[24] as markers
154 of advanced hepatic fibrosis or cirrhosis risk in the 46 participants (62.2%; 25 men, 21 women)

155 for whom the requisite data were available. We classified risks with FIB-4 as: low (FIB-4 < 1.3);
156 intermediate (1.3 ≤ FIB-4 ≤ 2.67); and high (FIB-4 > 2.67).[23] We classified risks with APRI as:
157 low (APRI < 0.05); intermediate (0.5 < APRI < 1.5); and high (APRI > 1.5).[24] We also compiled
158 participant reports of cirrhosis diagnoses.
159

160 **Statistics**

161 The dataset for analyses consisted of complete observations on 74 participants (37 men, 37
162 women) except FIB-4 and APRI indices (25 men, 21 women). Kolmogorov-Smirnov testing
163 demonstrated that age, BMI, daily intake of heme iron, TS, SF, and MCV data did not differ
164 significantly from those that are normally distributed. We displayed these data as means ± 1
165 standard deviation (SD) and compared means using the Student's t test for unpaired samples (two-
166 tailed). We displayed other continuous data as medians (ranges) and compared medians using the
167 Mann-Whitney U test (two-tailed). We compared binary data using Fisher's exact test (two-tailed).
168 We computed associations of MCV with available continuous variables using Pearson's correlation
169 (two-tailed) or Spearman's rank correlation (two-tailed) for paired data, as appropriate.
170

171 We evaluated these 11 independent variables for suitability in a linear regression on MCV: age,
172 BMI, sex, diabetes, intakes of heme, non-heme, and supplemental iron and alcohol, swollen or
173 tender 2nd/3rd MCP joints, TS, and SF. We deleted sex because it was significantly associated with
174 SF in a Bonferroni-corrected correlation matrix. A preliminary regression on MCV using the
175 remaining variables revealed low standardized beta coefficients (beta) and high values of p for
176 BMI, diabetes, non-heme iron intake, swollen or tender 2nd/3rd MCP joints, TS, and SF. Thus, we
177 excluded these independent variables. We report the contributions of significant remaining

independent variables to the final regression as beta and the proportion of variance in MCV explained by the independent variable(s) as R^2.

We used Excel® 2022 (Microsoft Corp., Redmond, WA, USA) and GraphPad Prism 8® (2018; GraphPad Software, San Diego, CA, USA). We defined $p < 0.05$ to be significant.

184 **Results**

185 **Characteristics of 74 *HFE* p.C282Y/p.H63D compound heterozygotes**

186 There were 37 men and 37 women of mean age of 59 ± 12 y. Mean MCV was 95.7 ± 4.0 fL. Mean
187 SF and Hb were higher in men (Table 2). Nine participants (12.2%; 4 men, 5 women) had MCV ≥
188 100.0 fL.

189

190 **Table 2.** *HFE* p.C282Y/p.H63D compound heterozygotes in post-screening evaluations[a]

Variable	Men (n = 37)	Women (n = 37)	Value of p
Mean age, y (SD)	57 ± 13	62 ± 12	0.0606
Mean body mass index, kg/m^2 (SD)	28.7 ± 5.0	28.0 ± 5.2	0.5405
Diabetes reports, % (n)	24.3 (6)	5.4 (2)	0.2611
Mean heme iron intake, mg/d (SD)	2.4 ± 1.4	1.9 ± 1.0	0.0549
Median non-heme iron intake, mg/d (range)	12.3 (4.2, 34.9)	12.2 (4.3, 43.7)	0.4822
Median supplemental iron intake, mg/d (range)	3.9 (0, 40.5)	3.9 (0, 40.5)	0.6892
Median alcohol intake, g/d (range)	5.7 (0, 60.9)	5.7 (0, 55.8)	0.7949
Swollen or tender 2nd/3rd MCP joints, % (n)	5.4 (2)	5.4 (2)	~1.0000
Mean transferrin saturation, % (SD)	58 ± 17	53 ± 12	0.1197
Mean serum ferritin, µg/L (SD)	531 ± 170	366 ± 201	0.0003
Mean hemoglobin, g/L	155 ±8	139 ± 9	< 0.0001
Mean corpuscular volume, fL (SD)	95.5 ± 4.0	96.0 ± 4.1 fL	0.6087

191 [a] MCP, metacarpophalangeal; SD, standard deviation

192 **Markers of advanced hepatic fibrosis**

193 High-risk FIB-4 indices were observed in five of 46 participants (10.9%), none of whom had a
194 high-risk APRI (Table 2). There was no significant difference in mean MCV by low, intermediate,
195 or high risk FIB-4 or APRI classification (Table 2). One woman reported that she was diagnosed
196 with cirrhosis, although both her FIB-4 and APRI risks were classified as intermediate.

197

198 **Table 2.** Hepatic fibrosis risk in 46 *HFE* p.C282Y/p.H63D compound heterozygotes[a]

	Low risk, % (n)	**Intermediate risk, % (n)**	**High risk, % (n)**	**Value of p**
FIB-4[b]	56.5 (26)	32.6 (15)	10.9 (5)	-
Mean MCV, fL (SD)	95.7 ± 3.5	96.3 ± 5.6	97.0 ± 5.1	0.8204[d]
APRI[c]	78.3 (36)	21.7 (10)	0 (0)	-
Mean MCV, fL (SD)	96.4 ± 4.0	94.8 ± 5.5	-	0.3140[e]

199 [a] APRI, AST-to-platelet ratio index; FIB-4, fibrosis-4 index; MCV, mean corpuscular volume; SD,
200 standard deviation

201 [b] low risk (FIB-4 < 1.3); intermediate risk (1.3 ≤ FIB-4 ≤ 2.67); and high risk (FIB-4 > 2.67).

202 [c] low risk (APRI < 0.05); intermediate risk (0.5 < APRI < 1.5); and high risk (APRI > 1.5).

203 [d] One-way ANOVA p test.

204 [e] Unpaired Student t test (two-tailed).

205

206 **MCV correlations with continuous variables**

207 There were significant positive correlations of MCV with age (Fig. 1, Table 3), daily heme iron
208 intake (Table 3), and daily alcohol intake (Fig. 2, Table 3), and a significant negative correlation
209 of MCV with BMI (Table 3).

210

211 **Table 3.** Correlations of mean corpuscular volume in 74 *HFE* p.C282Y/p.H63D compound
212 heterozygotes

Variable	**Pearson's coefficient r**	**Spearman's coefficient *r***	**Value of p**[a]
Age, y	0.2983	-	0.0098[a]
Body mass index, kg/m^2	−0.2299	-	0.0488
Heme iron intake, mg/d	−0.2478	-	0.0333
Non-heme iron intake, mg/d	-	−0.0604	0.6092
Supplemental iron intake, mg/d	-	0.0742	0.5300
Alcohol intake, g/d	-	0.2860	0.0135[b]
Transferrin saturation, %	0.0667	-	0.5723
Serum ferritin, µg/L	−0.0403	-	0.7296

213 [a] See Figure 1.

214 [b] See Figure 2.

215

216



217

218 **Figure 1.** Pearson's correlation of mean corpuscular volume vs. age in 74 *HFE* p.C282Y/p.H63D

219 compound heterozygotes with high iron phenotypes (r_{74} = 0.2983; p = 0.0098).

220



221

222 **Figure 2.** Spearman's rank correlation of mean corpuscular volume vs. daily alcohol intake in 74

223 *HFE* p.C282Y/p.H63D compound heterozygotes with high iron phenotypes (r_{74} = 0.2860; p =

224 0.0135).

225 **Mean MCV and binary variables**

226 Mean MCV did not differ significantly between men and women or between participants with and
227 without diabetes reports or swollen or tender 2nd/3rd MCP joints (Table 4).

228

229 **Table 4.** Mean corpuscular volume in 74 *HFE* p.C282Y/p.H63D compound heterozygotes[a]

Variable	Mean MCV, fL ± SD with variable (n)	Mean MCV, fL ± SD without variable (n)	Value of p
Male sex	95.5 ± 4.0 (37)	96.0 ± 4.1 (37)	0.6087
Diabetes reports	94.6 ± 3.3 (8)	95.8 ± 4.2 (66)	0.4045
Swollen or tender 2nd/3rd MCP joints	97.0 ± 5.5 (4)	95.6 ± 4.0 (70)	0.6768

230 [a] MCP, metacarpophalangeal; MCV, mean corpuscular volume; SD, standard deviation

231

232 **MCV and heavy alcohol intakes**

233 The mean MCV of the 19 participants (10 men, 9 women) with heavy alcohol intakes was greater
234 than the mean MCV of the other 55 participants (97.8 ± 3.8 vs. 95.0 ± 3.9, respectively; p =
235 0.0074). Four men and two women with heavy alcohol intakes had MCV ≥ 100 fL.

236

237 **Regression on MCV**

238 Linear regression on MCV using the independent variables age, daily heme iron intake, and daily
239 alcohol intake revealed positive associations with age (p = 0.0064; beta 0.3055) and daily alcohol
240 intake (p = 0.0151; beta 0.2707). The R^2 (adjusted R^2) was 0.1622 (0.1386). ANOVA p of this
241 regression was 0.0019.

242 **Discussion**

243 The novel findings of this study of 74 *HFE* p.C282Y/p.H63D compound heterozygotes with
244 elevated screening TS and SF are that MCV was significantly associated with both age and daily
245 alcohol intake after adjustment for other variables. An unexpected finding is that MCV was not
246 significantly associated with TS, in contrast to observations in p.C282Y homozygotes.[9 25 26 27]
247

248 Increasing MCV of the present *HFE* p.C282Y/p.H63D compound heterozygotes was associated
249 with increasing age. MCV also increased with age in post-screening p.C282Y homozygotes[27] and
250 English adults in primary care venues.[28] Increasing age[29] and MCV[30] are inversely related to
251 leukocyte telomere lengths (LTLs). In a Mendelian randomization study, an increase of one
252 standard deviation in genetically influenced telomere length decreased MCV significantly.[31] In
253 another study, mean LTL in p.C282Y homozygotes with and without elevated iron phenotypes did
254 not differ significantly.[32] These observations suggest that genetic determinants of telomere
255 length,[31] not *HFE* genotypes or iron phenotypes, account in part for the age-related increase in
256 MCV we observed in the present p.C282Y/p.H63D compound heterozygotes.
257

258 There was a moderate negative correlation of MCV with BMI in this study, although MCV was
259 not significantly associated with BMI after adjustment for other variables. In self-reported healthy
260 subjects aged > 18 y in the 2011-2016 National Health and Nutrition Examination Survey, there
261 was a weak negative association of MCV with BMI.[33]
262

263 Mean MCV of the present *HFE* p.C282Y/p.H63D compound heterozygotes with and without
264 diabetes reports did not differ significantly. The mean MCV of Scottish adults with diabetes was

265 significantly higher than that of control subjects.[34] In contrast, the mean MCV of Indian adults
266 with type 2 diabetes was significantly lower than that of control subjects.[35]
267
268 There was a weak positive correlation of MCV with daily heme iron intake in this study, although
269 MCV was not significantly associated with daily heme iron intake after adjustment for other
270 variables. In Dutch blood and plasma donors, MCV was positively associated with heme iron
271 intakes in men but not in women.[36]
272
273 MCVs of the present *HFE* p.C282Y/p.H63D compound heterozygotes were positively associated
274 with daily alcohol intakes. The mean MCV of Australian men and women with any p.C282Y
275 genotype also increased with alcohol intake after adjustment for age.[37] In the same study, neither
276 p.C282Y nor p.H63D alone predisposed to moderate or heavy alcohol intake.[37] In British adults
277 without anemia, MCV also increased with alcohol intake, but there was no interaction between
278 alcohol consumption and allelic variants associated with MCV.[38]
279
280 The present *HFE* p.C282Y/p.H63D compound heterozygotes were invited to attend post-screening
281 evaluations because their screening TS and SF values were elevated.[15] Heavy alcohol intake
282 occurred in 25.7% of the present compound heterozygotes, whereas heavy alcohol intake occurs
283 in ~6.5% of non-Hispanic white adults in the U.S.[21] Alcohol intake was excessive in 38.9% of
284 Australian p.C282Y/p.H63D compound heterozygotes with hemochromatosis and SF > 1000
285 μg/L.[39] Excessive alcohol intake increases TS[40 41] and SF.[42] These observations suggest that 1)
286 alcohol intake is a major cause of elevated MCV in p.C282Y/p.H63D compound heterozygotes
287 with both elevated TS and elevated SF and 2) the present post-screening examination invitation

288 criteria of both elevated TS and elevated SF preferentially although unintentionally selected
289 p.C282Y/p.H63D compound heterozygotes with heavy daily alcohol intakes.
290
291 Swollen or tender 2nd/3rd MCP joints were not associated with MCV and macrocytosis in this
292 study, in contrast to observations in *HFE* p.C282Y homozygotes.[27 43] The prevalence of swollen
293 or tender 2nd/3rd MCP joints in the present p.C282Y/p.H63D compound heterozygotes was lower
294 than that of post-screening participants with p.C282Y homozygosity (5.4% and 14.4%,
295 respectively; $p = 0.0246$).[27]
296
297 It was unexpected that MCVs in the present *HFE* p.C282Y/p.H63D compound heterozygotes were
298 not significantly associated with TS, in contrast to the positive associations between MCV and TS
299 in p.C282Y homozygotes.[9 26 27] Mean TS is significantly lower in untreated p.C282Y/p.H63D
300 compound heterozygotes than untreated p.C282Y homozygotes.[5] This suggests that the mean TS
301 in p.C282Y/p.H63D compound heterozygotes is insufficient to increase the uptake of transferrin-
302 bound iron by immature erythroid cells, increase Hb synthesis, and thereby increase MCV.[9]
303
304 Limitations of this study include the lack of observations of *HFE* p.C282Y/p.H63D participants
305 without both elevated TS and SF and of participants aged < 25 y.[5] The HEIRS Study did not
306 measure serum levels of vitamin B12 or folate, although none of the present subjects had anemia
307 and deficiencies of these micronutrients were uncommon causes of macrocytosis in another
308 primary care cohort.[44] More than three-quarters of the variance in MCV values in the present linear
309 regression is attributable to variables we did not analyze, especially non-*HFE* genetic factors.[11 31
310 38] Measuring iron stores using quantitative phlebotomy or liver specimens obtained by biopsy and

311 performing clinical evaluations for cirrhosis were beyond the scope of the cross-sectional HEIRS
312 Study.
313
314 None of 46 participants had combination of high-risk FIB-4 and APRI indices. It is unknown
315 whether any of the other 28 participants (37.8%) would have had high-risk FIB-4 and APRI indices
316 or not, although none of them reported a diagnosis of cirrhosis. The prevalence of documented
317 iron overload-related disease (including cirrhosis) was low in other cohorts of *HFE*
318 p.C282Y/p.H63D compound heterozygotes.[45 46] These observations suggest the prevalence of
319 occult advanced hepatic fibrosis or cirrhosis is also low in the present cohort and unlikely to
320 influence the present results significantly.
321
322 **Conclusion**
323 We conclude that MCV in *HFE* p.C282Y/p.H63D compound heterozygotes with high iron
324 phenotypes is positively associated with age and daily alcohol intake, after adjustment for other
325 variables.
326
327 **Acknowledgements**
328 The following individuals also performed data collection (2001-2003) and received compensation
329 for their work: Paul C. Adams, MD (Department of Medicine, London Health Sciences Centre,
330 London, Ontario, Canada); John H. Eckfeldt, MD, PhD (Department of Laboratory Medicine and
331 Pathology, University of Minnesota, Minneapolis); Victor R. Gordeuk, MD (Division of
332 Hematology and Oncology, Department of Medicine, University of Illinois at Chicago, Chicago);
333 Emily Harris, PhD (Epidemiology and Genomics Research Program, Division of Cancer Control

and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland); Helen Harrison, RN (The Western-Fanshawe Collaborative BScN Program, Fanshawe College, London, Ontario, Canada); Christine E. McLaren, PhD (Department of Epidemiology, University of California, Irvine, California); and Gordon D. McLaren, MD (Division of Hematology/Oncology, Department of Medicine, University of California, Irvine, and Department of Veterans Affairs Long Beach Healthcare System, Long Beach, California).

Authors' contributions

Each author contributed substantively to this study. JaCB conceived this study and its methodology, collected data, evaluated participants in post-screening evaluations, performed analyses, and drafted the manuscript. JClB conceived study methodology, curated data, performed analyses, and drafted the manuscript. RTA conceived this study and its methodology, collected data, performed analyses, curated data, and drafted the manuscript. Each author approved the manuscript in its final form.

Competing interest statement

The authors report no conflict of interest. The authors and their respective institutions have not received any payments or services in the past 36 months from a third party that could be perceived to influence, or give the appearance of potentially influencing, the submitted work.

Funding statement

The National Heart, Lung, and Blood Institute and the National Human Genome Research Institute had major roles in the HEIRS Study design, data collection, data analyses, and funding, but had

357 no role in the decision to publish the present work. The authors received additional funding from
358 Southern Iron Disorders Center for performing data curation and analysis and manuscript
359 composition pertinent to this submission.

360

361 **Data Sharing Statement**

362 The National Heart, Lung, and Blood Institute provides controlled access to individual participant
363 data through the Biologic Specimen and Data Repository Information Coordinating Center
364 (BioLINCC) (https://biolincc.nhlbi.nih.gov/studies/heirs/). Data access requires registration,
365 evidence of local institutional review board approval or certification of exemption from
366 institutional review board review, and completion of a data use agreement. The National Heart,
367 Lung, and Blood Institute does not permit investigators to submit data directly to journals, related
368 repositories, or other sources. Parties interested in obtaining the data analyzed in the present study
369 are referred to BioLINCC.

370

371

372 References

373

374 1. Barton JC, Edwards CQ, Acton RT. *HFE* gene: Structure, function, mutations, and
375 associated iron abnormalities. *Gene;*2015;**574**:179-192. doi: 10.1016/j.gene.2015.10.009

376 2. Girelli D, Busti F, Brissot P*, et al.* Hemochromatosis classification: update and
377 recommendations by the BIOIRON Society. *Blood;*2022;**139**:3018-3029. doi:
378 10.1182/blood.2021011338

379 3. Ganz T. Hepcidin and iron regulation, 10 years later. *Blood;*2011;**117**:4425-4433. doi:
380 10.1182/blood-2011-01-258467

381 4. Merryweather-Clarke AT, Pointon JJ, Shearman JD*, et al.* Global prevalence of putative
382 haemochromatosis mutations. *J Med Genet;*1997;**34**:275-278. doi: 10.1136/jmg.34.4.275

383 5. Adams PC, Reboussin DM, Barton JC*, et al.* Hemochromatosis and iron-overload
384 screening in a racially diverse population. *N Engl J Med;*2005;**352**:1769-1778. doi:
385 10.1056/NEJMoa041534

386 6. Means RTJr, Glader B. Anemia: general considerations. In: Means RT Jr, Rodgers GM,
387 Glader B et al., eds. Wintrobe's Clinical Hematology. Philadelphia: Wolters Kluwer;
388 2024:600-627.

389 7. Rossi E, Olynyk JK, Cullen DJ*, et al.* Compound heterozygous hemochromatosis genotype
390 predicts increased iron and erythrocyte indices in women. *Clin Chem;*2000;**46**:162-166.

391 8. Rossi E, Bulsara MK, Olynyk JK*, et al.* Effect of hemochromatosis genotype and lifestyle
392 factors on iron and red cell indices in a community population. *Clin Chem;*2001;**47**:202-
393 208.

394 9. Barton JC, Bertoli LF, Rothenberg BE. Peripheral blood erythrocyte parameters in
395 hemochromatosis: evidence for increased erythrocyte hemoglobin content. *J Lab Clin*
396 *Med;*2000;**135**:96-104. doi: 10.1016/s0022-2143(00)70026-6

397 10. de Valk B, Witlox RS, van der Schouw YT*, et al.* Biochemical expression of heterozygous
398 hereditary hemochromatosis. *Eur J Intern Med;*2000;**11**:317-321. doi: 10.1016/s0953-
399 6205(00)00111-4

400 11. Ganesh SK, Zakai NA, van Rooij FJ*, et al.* Multiple loci influence erythrocyte phenotypes
401 in the CHARGE Consortium. *Nat Genet;*2009;**41**:1191-1198. doi: 10.1038/ng.466

402 12. Kullo IJ, Ding K, Jouni H*, et al.* A genome-wide association study of red blood cell traits
403 using the electronic medical record. *PLoS One;*2010;**5**:e13011. doi:
404 10.1371/journal.pone.0013011

405 13. McLaren CE, Garner CP, Constantine CC*, et al.* Genome-wide association study identifies
406 genetic loci associated with iron deficiency. *PLoS One;*2011;**6**:e17390. doi:
407 10.1371/journal.pone.0017390

408 14. Feeney GP, Carter K, Masters GS*, et al.* Changes in erythropoiesis in hereditary
409 hemochromatosis are not mediated by HFE expression in nucleated red cells.
410 *Haematologica;*2005;**90**:180-187.

411 15. McLaren CE, Barton JC, Adams PC*, et al.* Hemochromatosis and Iron Overload Screening
412 (HEIRS) Study design for an evaluation of 100,000 primary care-based adults. *Am J Med*
413 *Sci;*2003;**325**:53-62. doi: 10.1097/00000441-200302000-00001

414 16. Hemochromatosis and Iron Overload Screening Study (HEIRS) January 2000-January
415 2006. Available at: https://biolincc.nhlbi.nih.gov/studies/heirs/. Accessed 16 October 2025.

416 17. Barton JC, Acton RT, Dawkins FW*, et al.* Initial screening transferrin saturation values,
417 serum ferritin concentrations, and *HFE* genotypes in whites and blacks in the
418 Hemochromatosis and Iron Overload Screening Study. *Genet Test;*2005;**9**:231-241. doi:
419 10.1089/gte.2005.9.231

420 18. McLaren GD, McLaren CE, Adams PC*, et al.* Clinical manifestations of hemochromatosis
421 in *HFE* C282Y homozygotes identified by screening. *Can J Gastroenterol;*2008;**22**:923-
422 930. doi: 10.1155/2008/907356

423 19. Nagao T, Hirokawa M. Diagnosis and treatment of macrocytic anemias in adults. *J Gen*
424 *Fam Med;*2017;**18**:200-204. doi: 10.1002/jgf2.31

425 20. Stram DO, Hankin JH, Wilkens LR*, et al.* Calibration of the dietary questionnaire for a
426 multiethnic cohort in Hawaii and Los Angeles. *Am J Epidemiol;*2000;**151**:358-370. doi:
427 10.1093/oxfordjournals.aje.a010214

428 21. Boersma, P., Villarroel, M. A., and Vahratian, A. Heavy Drinking Among U.S. Adults,
429 2018. Available at: https://www.cdc.gov/nchs/data/databriefs/db374-h.pdf. Accessed
430 September 15, 2025.

431 22. Eknoyan G. Adolphe Quetelet (1796-1874)--the average man and indices of obesity.
432 *Nephrol Dial Transplant;*2008;**23**:47-51. doi: gfm517 [pii];10.1093/ndt/gfm517 [doi]

433 23. Shah AG, Lydecker A, Murray K*, et al.* Comparison of noninvasive markers of fibrosis in
434 patients with nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol;*2009;**7**:1104-
435 1112. doi: 10.1016/j.cgh.2009.05.033

436 24. Borroni G, Ceriani R, Cazzaniga M*, et al.* Comparison of simple tests for the non-invasive
437 diagnosis of clinically silent cirrhosis in chronic hepatitis C. *Aliment Pharmacol*
438 *Ther;*2006;**24**:797-804. doi: 10.1111/j.1365-2036.2006.03034.x

439 25. McLaren CE, Barton JC, Gordeuk VR*, et al.* Determinants and characteristics of mean
440 corpuscular volume and hemoglobin concentration in white *HFE* C282Y homozygotes in
441 the Hemochromatosis and Iron Overload Screening Study. *Am J Hematol;*2007;**82**:898-
442 905. doi: 10.1002/ajh.20937

443 26. Adris N, Hazeldine S, Bentley P*, et al.* Detection of *HFE* haemochromatosis in the clinic
444 and community using standard erythrocyte tests. *Blood Cells Mol Dis;*2019;**74**:18-24. doi:
445 10.1016/j.bcmd.2018.10.003

446 27. Barton JC, Barton JC, Acton RT. Factors related to mean corpuscular volume in *HFE*
447 p.C282Y homozygotes. *ejHaem;*2024;**6**:e1063. doi: 10.1002/jha2.1063

448 28. Phillips R, Wood H, Weaving G*, et al.* Changes in full blood count parameters with age
449 and sex: results of a survey of almost 900 000 patient samples from primary care. *Br J*
450 *Haematol;*2021;**192**:e102-e105. doi: 10.1111/bjh.17290

451 29. Frenck RW, Jr., Blackburn EH, Shannon KM. The rate of telomere sequence loss in human
452 leukocytes varies with age. *Proc Natl Acad Sci U S A;*1998;**95**:5607-5610. doi:
453 10.1073/pnas.95.10.5607

454 30. Kozlitina J, Garcia CK. Red blood cell size is inversely associated with leukocyte telomere
455 length in a large multi-ethnic population. *PLoS One;*2012;**7**:e51046. doi:
456 10.1371/journal.pone.0051046

457 31. Adams CD, Boutwell BB. A Mendelian randomization study of telomere length and blood-
458 cell traits. *Sci Rep;*2020;**10**:12223. doi: 10.1038/s41598-020-68786-6

459 32. Mainous AG, III, Wright RU, Hulihan MM*, et al.* Telomere length and elevated iron: the
460 influence of phenotype and *HFE* genotype. *Am J Hematol;*2013;**88**:492-496. doi:
461 10.1002/ajh.23438

462 33. Thavaraputta S, Dennis JA, Ball S*, et al.* Relation of hematologic inflammatory markers
463 and obesity in otherwise healthy participants in the National Health and Nutrition
464 Examination Survey, 2011-2016. *Proc (Bayl Univ Med Cent);*2020;**34**:17-21. doi:
465 10.1080/08998280.2020.1799482

466 34. Davidson RJ, Evan-Wong LA, Stowers JM. The mean red cell volume in diabetes mellitus.
467 *Diabetologia;*1981;**20**:583-584. doi: 10.1007/BF00252770

468 35. Basak M, Dey SK, Ghosh S*, et al.* A clinicopathological investigation on morphological
469 alterations of red blood cells among treated and untreated type II diabetes mellitus patients.
470 *Indian J Pathol Microbiol;*2025 doi: 10.4103/ijpm.ijpm_99_25

471 36. Timmer TC, de GR, Rijnhart JJM*, et al.* Dietary intake of heme iron is associated with
472 ferritin and hemoglobin levels in Dutch blood donors: results from Donor InSight.
473 *Haematologica;*2020;**105**:2400-2406. doi: 10.3324/haematol.2019.229450

474 37. Olynyk JK, Knuiman MW, Divitini ML*, et al.* Effects of *HFE* gene mutations and alcohol
475 on iron status, liver biochemistry and morbidity. *J Gastroenterol Hepatol;*2005;**20**:1435-
476 1441. doi: 10.1111/j.1440-1746.2005.03967.x

477 38. Thompson A, King K, Morris AP*, et al.* Assessing the impact of alcohol consumption on
478 the genetic contribution to mean corpuscular volume. *Hum Mol Genet;*2021;**30**:2040-2051.
479 doi: 10.1093/hmg/ddab147

480 39. Walsh A, Dixon JL, Ramm GA*, et al.* The clinical relevance of compound heterozygosity
481 for the C282Y and H63D substitutions in hemochromatosis. *Clin Gastroenterol*
482 *Hepatol;*2006;**4**:1403-1410. doi: 10.1016/j.cgh.2006.07.009

483 40. Whitfield JB, Zhu G, Heath AC*, et al.* Effects of alcohol consumption on indices of iron
484 stores and of iron stores on alcohol intake markers. *Alcohol Clin Exp Res;*2001;**25**:1037-
485 1045.

486 41. Kroll DS, McPherson KL, Manza P*, et al.* Elevated transferrin saturation in individuals
487 with alcohol use disorder: association with *HFE* polymorphism and alcohol withdrawal
488 severity. *Addict Biol;*2022;**27**:e13144. doi: 10.1111/adb.13144

489 42. Milman N, Kirchhoff M. Relationship between serum ferritin, alcohol intake, and social
490 status in 2235 Danish men and women. *Ann Hematol;*1996;**72**:145-151. doi:
491 10.1007/s002770050153

492 43. Rehman A, Carroll GJ, Powell LW*, et al.* Arthropathy in hereditary haemochromatosis
493 segregates with elevated erythrocyte mean corpuscular volume. *Scand J*
494 *Rheumatol;*2021;**50**:139-142. doi: 10.1080/03009742.2020.1800081

495 44. Wymer A, Becker DM. Recognition and evaluation of red blood cell macrocytosis in the
496 primary care setting. *J Gen Intern Med;*1990;**5**:192-197. doi: 10.1007/BF02600531

497 45. Gurrin LC, Bertalli NA, Dalton GW*, et al. HFE* C282Y/H63D compound heterozygotes
498 are at low risk of hemochromatosis-related morbidity. *Hepatology;*2009;**50**:94-101. doi:
499 10.1002/hep.22972

500 46. Hasan SMM, Farrell J, Borgaonkar M. C282Y/H63D compound heterozygosity is a low
501 penetrance genotype for iron overload-related disease. *J Can Assoc*
502 *Gastroenterol;*2022;**5**:240-247. doi: 10.1093/jcag/gwac025

503

504